<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Central nervous system tuberculosis: Treatment and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Central nervous system tuberculosis: Treatment and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Central nervous system tuberculosis: Treatment and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ravindra Kumar Garg, MD, DM, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Bernardo, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 26, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H377053487">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Forms of central nervous system (CNS) infection due to
         <em>
          Mycobacterium tuberculosis
         </em>
         include meningitis, tuberculoma, and spinal arachnoiditis [
         <a href="#rid1">
          1-6
         </a>
         ].
        </p>
        <p>
         Issues related to management of CNS tuberculosis (TB) will be reviewed here. The epidemiology and pathogenesis, clinical manifestations, and diagnosis of CNS TB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">
          "Central nervous system tuberculosis: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128000.html" rel="external">
          "Tuberculous meningitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Issues related to pulmonary TB and miliary TB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7026.html" rel="external">
          "Pulmonary tuberculosis: Clinical manifestations and complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8029.html" rel="external">
          "Epidemiology and pathology of miliary and extrapulmonary tuberculosis"
         </a>
         .)
        </p>
        <p>
         Issues related to treatment of TB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p>
         Issues related to treatment of TB in patients with HIV infection are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8030.html" rel="external">
          "Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2453815193">
         <span class="h1">
          TUBERCULOUS MENINGITIS
         </span>
        </p>
        <p class="headingAnchor" id="H1173529151">
         <span class="h2">
          Treatment
         </span>
        </p>
        <p class="headingAnchor" id="H75095126">
         <span class="h3">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of tuberculous meningitis consists of prompt administration of antituberculous therapy, together with glucocorticoids. For patients with hydrocephalus, surgical consultation is warranted. Issues related to management of hyponatremia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults"
         </a>
         .)
        </p>
        <p>
         Empiric treatment should
         <strong>
          not
         </strong>
         be delayed, given the high mortality and complication rate of untreated infection (see
         <a class="local">
          'Outcomes'
         </a>
         below). Initiation of empiric treatment is warranted for patients with relevant epidemiologic factors (history of prior tuberculosis [TB] infection or disease, known or possible TB exposure, and/or past or present residence in or travel to an area where TB is endemic), clinical manifestations (subacute presentation of stiff neck, headache, fever and vomiting), pertinent radiographic findings (such as hydrocephalus, basilar meningeal thickening, edema and/or tuberculomas), and typical cerebrospinal fluid (CSF) findings (lymphocytic pleocytosis, elevated protein concentration, and low glucose concentration).
        </p>
        <p>
         The likelihood of a favorable clinical outcome is increased with early initiation of therapy; treatment delay (even for a few days) may be associated with increased likelihood of unfavorable outcome [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="local">
          'Outcomes'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3059037094">
         <span class="h3">
          Antituberculous therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The principles of treatment of tuberculous meningitis are derived from those governing the management of pulmonary TB. The treatment regimens outlined below reflect guidance from United States Centers for Disease Control and Prevention (CDC), British Society guidelines, and World Health Organization (WHO) guidelines for treatment of central nervous system (CNS) TB [
         <a href="#rid1">
          1,5,7
         </a>
         ]. The evidence for treatment of pulmonary TB is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Antituberculous therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2932304551">
         <span class="h4">
          Drug susceptible disease
         </span>
        </p>
        <p class="headingAnchor" id="H3398220053">
         <span class="h5">
          Traditional regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, treatment of CNS TB consists of an initial intensive phase (four drugs administered for two months) followed by a prolonged continuation phase (usually two drugs administered for an additional 7 to 10 months), for a total treatment duration of 9 to 12 months. Ideally all patients with TB should be treated with clinical case management and directly observed therapy. (See
         <a class="medical medical_review" href="/z/d/html/8019.html" rel="external">
          "Adherence to tuberculosis treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intensive phase
         </strong>
         − Empiric intensive phase drug regimens consist of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults
         </strong>
         − For empiric treatment of CNS TB (not known or suspected to be drug resistant) in adults, the intensive-phase four-drug regimen consists of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and a fourth agent administered daily for two months [
         <a href="#rid1">
          1,5,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The approach to selection of a fourth drug is uncertain due to lack of clinical trial data to guide selection of an alternative. Use of
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         is limited by its poor cerebrospinal fluid (CNS) penetration [
         <a href="#rid8">
          8
         </a>
         ]. Other options include
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         , which have better CNS penetration than ethambutol. The WHO 2010 guidelines favored use streptomycin over ethambutol as a fourth drug [
         <a href="#rid9">
          9
         </a>
         ]; however, a subsequent WHO 2022 statement favored use of ethambutol as a fourth drug in adults [
         <a href="#rid1">
          1
         </a>
         ]. The CDC/ATS/IDSA 2016 guidance also favors use of ethambutol as a fourth drug [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          Isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         are bactericidal, penetrate inflamed meninges, and achieve CSF levels that exceed the minimum inhibitory concentration for sensitive strains. Isoniazid has excellent CNS penetration and is more active against rapidly dividing than against semi-dormant organisms. Rifampin is active against both rapidly dividing organisms and semi-dormant organisms, despite its relatively poor CNS penetration [
         <a href="#rid10">
          10
         </a>
         ]. Pyrazinamide readily penetrates the CNS and is highly active against intracellular mycobacteria.
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          Streptomycin
         </a>
         is considered to have weak bactericidal properties.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Adult drug doses are summarized in the tables  (
         <a class="graphic graphic_table graphicRef127916" href="/z/d/graphic/127916.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Use of higher-dose
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         during the intensive phase has not been associated with improved survival. In a randomized trial including 817 patients with tuberculous meningitis (of whom 349 had human immunodeficiency virus [HIV] infection), patients were randomly assigned to treatment with a standard regimen or an intensified regimen that included higher-dose rifampin (15 mg/kg per day) and levofloxacin (20 mg/kg per day) during the intensive phase; during nine months of follow-up, no survival benefit was observed between the groups (survival probability approximately 75 percent) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Use of even higher
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         dosing (&gt;30 mg/kg) warrants further study; this may improve CSF penetration and may overcome the issue of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         monoresistance [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children
         </strong>
         – For empiric treatment of CNS TB (not known or suspected to be drug resistant) in children, we are in agreement with the American Academy of Pediatrics which recommends treatment with an intensive phase four-drug regimen consisting of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and either
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         or
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         (in place of
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , given poor CNS penetration and difficulty with monitoring for ethambutol-associated optic neuritis) administered daily for two months [
         <a href="#rid4">
          4
         </a>
         ]. When used to treat CNS TB, rifampin should be given at a dose of 20 to 30 mg/kg/day to ensure adequate CNS penetration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If/when susceptibility to first-line drugs is established, the
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         or aminoglycoside may be discontinued.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Pediatric drug doses are summarized in the tables  (
         <a class="graphic graphic_table graphicRef127916" href="/z/d/graphic/127916.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef50271" href="/z/d/graphic/50271.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef88543" href="/z/d/graphic/88543.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continuation phase
         </strong>
         − In the setting of infection known or presumed to be caused by susceptible strains, the continuation phase consists of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         and
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         (given daily), continued for 7 to 10 months [
         <a href="#rid1">
          1,5,7
         </a>
         ]. The optimal duration of treatment is uncertain; in general, an extended period of treatment is administered because tuberculous meningitis is associated with high rates of disability and deaths. In one review and meta-analysis comparing six months versus longer treatment duration for tuberculous meningitis with at least isoniazid, rifampin, and
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , there was no difference in two-year relapse rate between groups (1.5 versus 0 percent) [
         <a href="#rid14">
          14
         </a>
         ], suggesting six months might be sufficient.
        </p>
        <p>
        </p>
        <p>
         The treatment regimen should be tailored to the drug susceptibility data (when available) and clinical response.
        </p>
        <p>
         Following initiation of antituberculous therapy, paradoxical worsening of clinical manifestations may occur. (See
         <a class="local">
          'Paradoxical worsening'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3544229936">
         <span class="h5">
          Shortened regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the WHO stated in 2021 that an alternative shortened regimen (six-month regimen of daily
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ) may be used as an alternative treatment approach for children and adolescents [
         <a href="#rid3">
          3
         </a>
         ], we continue to favor use of the traditional regimen pending further data. The shortened regimen should be used only for patients without HIV infection and with no evidence of drug-resistant TB [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         A six-month regimen of daily
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         has been evaluated as an alternative option for the treatment of children and adolescents with tuberculous meningitis [
         <a href="#rid3">
          3
         </a>
         ]. In a systematic review and meta-analysis including three studies and more than 1000 participants, lower mortality (5 versus 24 percent) and higher treatment success rate (94 versus 75 percent) but more frequent neurologic sequelae among survivors (66 versus 36 percent) were observed with the shortened regimen compared with the traditional regimen [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H181714130">
         <span class="h4">
          Drug resistant infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of
         <em>
          M. tuberculosis
         </em>
         strains resistant to one or more first-line drugs is increasing [
         <a href="#rid16">
          16
         </a>
         ]. Risk factors for drug-resistant TB are summarized in the table  (
         <a class="graphic graphic_table graphicRef108729" href="/z/d/graphic/108729.html" rel="external">
          table 5
         </a>
         ). The presence of risk factors should prompt susceptibility testing (by molecular and conventional methods) on diagnostic specimens. (See
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults", section on 'Drug susceptibility testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults", section on 'Molecular testing'
         </a>
         .)
        </p>
        <p>
         The optimal approach to treatment of drug-resistant tuberculous meningitis is uncertain:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of isoniazid-resistant tuberculous meningitis, we favor intensive phase treatment with daily
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and a fluoroquinolone for two months, followed by a continuation phase of rifampin, pyrazinamide, and a fluoroquinolone for at least 10 months [
         <a href="#rid2">
          2,7,17
         </a>
         ]. This approach is derived from management of drug-resistant pulmonary TB, the evidence for which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of multidrug-resistant tuberculous meningitis, regimen selection should be guided by the approach to treatment of pulmonary disease; the regimen should include any first-line drugs to which the isolate is susceptible, with addition of a fluoroquinolone and additional second-line drugs with good CSF penetration (such as
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         and
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         ) to make a regimen including at least five effective drugs  (
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid18">
          18
         </a>
         ]. A combination of
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         , kanamycin, ethionamide,
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         , and
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         is a favorable regimen for multidrug-resistant tuberculous meningitis; kanamycin penetration is adequate if meninges are inflamed [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data on CSF penetration of
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         ,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         and delamanid are limited [
         <a href="#rid20">
          20,21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The optimal duration of therapy for treatment of drug-resistant CNS disease is uncertain. It may be advisable to extend the duration of therapy to 18 to 24 months, considering the severity of illness, the clinical response, and the patient's immune status. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3552332118">
         <span class="h3">
          Antiretroviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV infection are treated with the same antituberculous therapy as patients without HIV infection as described above. (See
         <a class="local">
          'Antituberculous therapy'
         </a>
         above.)
        </p>
        <p>
         In patients on antituberculous therapy, administration of antiretroviral therapy (ART) requires careful attention to potential interactions, particularly with rifamycins.
        </p>
        <p>
         For patients already on ART prior to diagnosis of CNS TB, modification of the ART regimen may be required in some cases. The approach to selection of ART in patients with CNS TB and HIV infection is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         .)
        </p>
        <p>
         For patients with CNS TB who are ART-naïve, we are in agreement with CDC/ATS/IDSA guidelines recommending that initiation of ART should be delayed for the first eight weeks of antituberculous therapy, regardless of CD4 count [
         <a href="#rid5">
          5
         </a>
         ]. This is because initiation of ART may be complicated by the immune reconstitution inflammatory syndrome (IRIS), which can manifest as progression of TB disease or clinical deterioration in patients previously improving on antituberculous therapy. However, guidance issued by the United States Department of Health and Human Services (DHHS) states that it is unclear whether the available data are generalizable to higher resourced settings; some favor starting ART within the first 2 to 8 weeks after starting antituberculous treatment (opting for the first two weeks in those with CD4 &lt;50 cells/mcL) in settings where close monitoring of drug-related toxicities and CNS adverse events is feasible [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="local">
          'Paradoxical worsening'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome"
         </a>
         .)
        </p>
        <p>
         Deferral of ART for the first eight weeks of antituberculous therapy is supported by a randomized trial including 253 patients with tuberculous meningitis and HIV infection (mean CD4 count 41 cells/mcL) treated with immediate or deferred ART (two months after randomization) [
         <a href="#rid23">
          23
         </a>
         ]; there was no significant difference in 9-month mortality (hazard ratio [HR] 1.12, 95% CI 0.81-1.55) or time to new acquired immunodeficiency syndrome (AIDS) event or death (HR 1.16, 95% CI 0.87-1.55) between the groups; however, life-threatening adverse events occurred more frequently among those who received immediate ART than those who received deferred ART (80 versus 69 percent).
        </p>
        <p class="headingAnchor" id="H1670987164">
         <span class="h3">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         We are in agreement with the WHO which recommends six to eight weeks of adjunctive glucocorticoid therapy for patients with tuberculous meningitis (suspected or confirmed). We administer glucocorticoids to patients with and without HIV infection.
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         can be given. After six to eight weeks, glucocorticoids should be tapered off [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Our approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients &gt;14 years of age −
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         0.3 to 0.4 mg/kg/day intravenously (IV) for 2 weeks, then 0.2 mg/kg/day IV week 3, then 0.1 mg/kg/day IV week 4, then 4 mg per day orally and taper 1 mg off the daily dose each week; total duration approximately eight weeks [
         <a href="#rid24">
          24,25
         </a>
         ]. In conscious patients, oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         0.5 mg/kg (up to 40 mg/day) may be given for four weeks and then tapered over the following four weeks [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients ≤14 years of age −
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         0.6 mg/kg/day IV for four weeks, followed by a reducing course over four weeks [
         <a href="#rid7">
          7
         </a>
         ]. An alternative (oral) regimen consists of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         2 mg/kg daily (maximum 60 mg/day), or its equivalent for four to six weeks, followed by tapering [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The above approach is supported by data from randomized trials demonstrating a mortality benefit associated with use of adjunctive glucocorticoid therapy in patients without HIV infection [
         <a href="#rid24">
          24,28-31
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of nine trials including 1337 children and adults with tuberculous meningitis, glucocorticoid therapy was associated with a lower mortality rate over 2 to 24 months follow-up (31 versus 41 percent [risk ratio 0.75, 95% CI 0.65-0.87]) [
         <a href="#rid30">
          30
         </a>
         ]. Rates of disabling neurologic deficits and serious adverse events were similar among treatment groups. The efficacy of corticosteroid therapy also appeared similar across categories of disease severity. Most (93 percent) of the patients in this analysis were HIV negative.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One randomized trial in 545 adolescents and adults compared the relative efficacy in those with and without HIV infection (98 and 446 participants respectively) [
         <a href="#rid24">
          24
         </a>
         ]. In a subgroup analysis, the relative risk reduction in mortality appeared similar for patients with and without HIV infection, but the analysis was underpowered to show a difference.
        </p>
        <p>
        </p>
        <p>
         Among patients with advanced HIV infection, adjunctive glucocorticoids do not appear to confer benefit based on available data:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a trial including 520 adults with tuberculous meningitis and HIV in Vietnam and Indonesia (of whom 51.9 percent had baseline CD4 cell count ≤50 per cubic millimeter and 49 percent had not received prior antiretroviral therapy), patients were treated with antituberculosis therapy and antiretroviral therapy and randomly assigned to receive either
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (six to eight week taper) or placebo [
         <a href="#rid32">
          32
         </a>
         ]. During 12-month follow-up, death rates were comparable between the groups (44 versus 49 percent; hazard ratio, 0.85; 95% confidence interval, 0.66 to 1.10). The incidence of IRIS during the first six months (a secondary endpoint) was similar between the two groups, as was the number of participants with at least one serious adverse event (73.0 versus 75.5 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is uncertain whether a larger trial might have shown a small mortality reduction; in addition, it is uncertain whether the profound immunosuppression among the patients enrolled in this study may have influenced the effect of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         on outcome and/or risk of adverse events. It is also uncertain whether the trial findings are generalizable to settings with better access to ventriculo-peritoneal shunting for management of hydrocephalus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pending further study, the possibility of a small reduction in mortality (not excluded by the above trial), with no significant added adverse effects, justifies use of corticosteroids for patients with TB meningitis and HIV infection – given the significant mortality and long-term disability associated with this condition [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Further study of other approaches to anti-inflammatory therapy, such as tumor necrosis factor-alpha (TNF-alpha) inhibition, is needed [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2050793811">
         <span class="h2">
          Management of complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical manifestations and diagnosis of complications of tuberculous meningitis are described separately. (See
         <a class="medical medical_review" href="/z/d/html/128000.html" rel="external">
          "Tuberculous meningitis: Clinical manifestations and diagnosis", section on 'Complications'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hydrocephalus
         </strong>
         − Progressively enlarging ventricles may manifest with elevated intracranial pressure, which can be life-threatening. Progressive ventriculomegaly can clinically manifest with increasing intracranial tension. Patients with progressive vision impairment and unconsciousness should be considered for CSF diversion via ventriculoperitoneal shunt or endoscopic third ventriculostomy [
         <a href="#rid35">
          35-38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111138.html" rel="external">
          "Hydrocephalus in children: Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyponatremia
         </strong>
         − The approach to management of hyponatremia is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Optochiasmatic arachnoiditis
          </em>
         </strong>
         <em>
          − Optochiasmatic arachnoiditis,
         </em>
         encasement of optic nerves and optic chiasma by thick tuberculous exudates, is an important cause of vision loss in tuberculous meningitis. This condition may develop paradoxically, despite administration of appropriate antituberculous therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal management of this complication is uncertain. Some patients regain vision with antituberculous therapy and corticosteroids. Neurosurgery may be considered in patients who do not respond to these interventions.
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          Thalidomide
         </a>
         , an inhibitor of tumor necrosis factor-alpha, has been associated with clinical improvement in isolated case reports [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3314737265">
         <span class="h2">
          Follow-up monitoring
         </span>
        </p>
        <p class="headingAnchor" id="H2985579661">
         <span class="h3">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Careful and regular clinical monitoring, including serial neurologic examinations to assess for mental status change and emerging focal deficits, is an essential component of follow-up. The risk of clinical deterioration and death is high during the intensive phase of treatment, and complications may arise or progress unexpectedly. The most challenging complications include hydrocephalus, hyponatremia, tuberculoma, and brain ischemia/infarction. (See
         <a class="medical medical_review" href="/z/d/html/128000.html" rel="external">
          "Tuberculous meningitis: Clinical manifestations and diagnosis", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">
          "Central nervous system tuberculosis: An overview", section on 'Tuberculoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">
          "Initial assessment and management of acute stroke"
         </a>
         .)
        </p>
        <p>
         The approach to use of follow-up laboratory and radiographic studies should be guided by individual clinical circumstances and are contingent upon a number of factors; these include patient age, clinical stage of illness at which treatment is initiated, presence and severity of complications, initial response to therapy, and certainty of diagnosis.
        </p>
        <p>
         Once adequate CSF specimens have been collected for diagnostic purposes, indications for follow-up lumbar puncture include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnostic uncertainty and unsatisfactory response to therapy during the intensive phase of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of atypical features of potential importance on initial CSF examination (such as neutrophilic predominance and unusually high protein concentration, which may be suggestive of emerging spinal block).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of elevated intracranial pressure in the setting of communicating hydrocephalus, for which lumbar puncture is needed for monitoring and temporary management.
        </p>
        <p>
        </p>
        <p>
         Follow-up radiographic imaging is useful to assess response to treatment in patients with complications such as hydrocephalus, tuberculoma, and brain infarction. Follow-up imaging should be done in patients with poor response to treatment, patients with rapid clinical deterioration, and patients with suspected paradoxical reaction.
        </p>
        <p>
         Antituberculous drugs are associated with a broad array of adverse effects. Hepatotoxicity is an important adverse effect that warrants careful clinical attention. Issues related to clinical monitoring during antituberculous therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Regimen adjustments for drug intolerance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview", section on 'Clinical and laboratory monitoring'
         </a>
         .)
        </p>
        <p>
         For patients who initiate empiric antituberculous therapy in the setting of suspected CNS TB but in the absence of definitive diagnosis, the course of treatment should be completed unless an alternative diagnosis is established [
         <a href="#rid7">
          7
         </a>
         ]. The clinical response to treatment, whether favorable or unfavorable, should not be used to determine whether to continue therapy.
        </p>
        <p class="headingAnchor" id="H992212693">
         <span class="h3">
          Paradoxical worsening
         </span>
         <span class="headingEndMark">
          —
         </span>
         After initiation of antituberculous therapy, paradoxical worsening of clinical manifestations may occur  (
         <a class="graphic graphic_diagnosticimage graphicRef127932" href="/z/d/graphic/127932.html" rel="external">
          image 1
         </a>
         ). The mechanism of paradoxical reaction is not known; it has been hypothesized to occur because of an exaggerated immune response to mycobacterial antigens.
        </p>
        <p>
         In one study including 141 patients with tuberculous meningitis (of whom 13 had HIV infection), paradoxical worsening was observed in approximately one-third of cases; in most cases such findings were observed within three months of starting antituberculous therapy [
         <a href="#rid40">
          40
         </a>
         ]. Risk factors for paradoxical worsening included female sex, concomitant HIV infection, and a shorter duration of illness prior to clinical presentation.
        </p>
        <p>
         Among patients with HIV infection, paradoxical worsening typically occurs after initiation of ART and is known as IRIS. The risk of IRIS is increased in patients with an initial CD4 count below 100/microL and in patients with a rapid fall in viral load and rise in CD4 count [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Manifestations of CNS disease progression in the setting of IRIS include meningitis, intracranial tuberculoma, brain abscess, radiculomyelitis, and spinal epidural abscess [
         <a href="#rid41">
          41-44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome", section on 'Tuberculosis'
         </a>
         .)
        </p>
        <p>
         The diagnosis of IRIS is one of exclusion. Patients should be evaluated with radiographic imaging and CSF examination if feasible; CSF examination may demonstrate neutrophilic predominance [
         <a href="#rid40">
          40,45,46
         </a>
         ]. Additional diagnostic considerations include nonadherence to therapy, drug-resistant infection, and other opportunistic infections. (See
         <a class="medical medical_review" href="/z/d/html/128000.html" rel="external">
          "Tuberculous meningitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Management of TB-associated IRIS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8030.html" rel="external">
          "Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy", section on 'Immune reconstitution inflammatory syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H882213457">
         <span class="h1">
          TUBERCULOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations and diagnosis of tuberculoma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">
          "Central nervous system tuberculosis: An overview", section on 'Tuberculoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1761330955">
         <span class="h2">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of tuberculoma consists of antituberculous therapy; the approach is the same as for treatment of tuberculous meningitis, as discussed above. (See
         <a class="local">
          'Antituberculous therapy'
         </a>
         above.)
        </p>
        <p>
         In TB-endemic areas, intracranial tuberculoma may persist following comprehensive antituberculous therapy; in some cases they persist for several years. It is uncertain whether persistent tuberculoma represents active disease or revascularization of a healing lesion; most experts believe that persistent tuberculoma does not represent treatment failure and that prolonged antituberculous therapy in an otherwise asymptomatic patient is not needed [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         No trials have evaluated whether patients with tuberculoma benefit from adjunctive glucocorticoids. We favor their use for patients with cerebral edema (particularly when edema is out of proportion to mass effect in the setting of associated altered mental status or focal neurologic deficits), increased intracranial pressure, and/or presence of concomitant meningitis. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
         Surgical consultation is warranted for patients with obstructive hydrocephalus or brainstem compression.
        </p>
        <p class="headingAnchor" id="H237371506">
         <span class="h2">
          Follow-up monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no guidelines or clinical series data upon which to base the approach to frequency of follow-up radiographic imaging in patients with tuberculoma. Important considerations include the location and size of the tuberculoma, the degree of associated cerebral edema, the character of neurologic signs, and clinical progress on therapy. In patients whose lesion is not in a critical location, with minimal to absent ongoing neurologic signs, we obtain follow-up imaging at two weeks, one month, three months, and six months of therapy.
        </p>
        <p>
         Additional issues related to follow-up monitoring are discussed above. (See
         <a class="local">
          'Follow-up monitoring'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3201027542">
         <span class="h1">
          SPINAL ARACHNOIDITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations and diagnosis of spinal arachnoiditis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">
          "Central nervous system tuberculosis: An overview", section on 'Spinal arachnoiditis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4192697059">
         <span class="h2">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of spinal arachnoiditis consists of antituberculous therapy, as discussed above. (See
         <a class="local">
          'Antituberculous therapy'
         </a>
         above.)
        </p>
        <p>
         In the setting of spinal arachnoiditis (particularly in the setting of multilevel disease), an extension of the treatment duration up to 18 months may be warranted, tailored to individual clinical circumstances.
        </p>
        <p>
         No trials have evaluated whether patients with spinal arachnoiditis benefit from adjunctive glucocorticoids. We favor their use in patients with spinal block (cerebrospinal fluid protein ≥500 mg/dL) and in patients with acute cord compression. Patients with concomitant meningitis should be treated as well. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
         Surgical intervention (excision, decompression) plays a limited but important role in select patients with certain forms of spinal tuberculosis (TB) who are not responding satisfactorily to medical treatment [
         <a href="#rid48">
          48
         </a>
         ]. These include intramedullary tuberculoma, extramedullary intradural tuberculoma, spinal tuberculous abscess, or local compression due to spinal arachnoiditis.
        </p>
        <p>
         Additional issues related to surgery for patients with spinal TB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7658.html" rel="external">
          "Bone and joint tuberculosis", section on 'Surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H360327110">
         <span class="h2">
          Follow-up monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to follow-up monitoring are discussed above. (See
         <a class="local">
          'Follow-up monitoring'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2144770045">
         <span class="h1">
          TRANSVERSE MYELITIS
         </span>
        </p>
        <p class="headingAnchor" id="H3508534298">
         <span class="h2">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of tuberculous transverse myelitis consists of antituberculous therapy and glucocorticoids; the approach is the same as for treatment of tuberculous meningitis, as discussed above. (See
         <a class="local">
          'Antituberculous therapy'
         </a>
         above and
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3813110949">
         <span class="h2">
          Follow-up monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to follow-up monitoring are discussed above. (See
         <a class="local">
          'Follow-up monitoring'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4271630447">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a 2022 meta-analysis including six studies and 663 patients hospitalized with tuberculous meningitis, the mortality rate was 42 percent [
         <a href="#rid49">
          49
         </a>
         ]. Late sequelae of tuberculous meningitis include cranial nerve palsies, gait disturbance, hemiplegia, blindness, deafness, learning disabilities, dementia, and syndromes of hypothalamic and pituitary dysfunction [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Among patients with tuberculous meningitis, the clinical outcome depends on the extent of disease at the time of treatment initiation. In one study including 48 patients with tuberculous meningitis admitted to intensive care, the mortality rate was 65 percent; factors associated with poor outcome included clinical stage at admission and delay in treatment initiation ≥3 days
         <em>
         </em>
         [
         <a href="#rid50">
          50
         </a>
         ]. In addition, four-drug antituberculous therapy was administered in 10 percent of cases; most patients were treated with ≤2 antituberculous agents. In another study including 52 patients with tuberculous meningitis, the mortality rate among patients who started treatment prior to clinical stage-1 or early stage-2 disease was less than 10 percent; of 11 patients with stage-3 disease, six died or suffered severe neurologic sequelae [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Radiographic findings may be useful predictors of outcome in some circumstances; patients with a normal computed tomography scan often recover with appropriate antituberculous therapy, whereas presence of hydrocephalus and marked basilar enhancement carries a poor prognosis. Tuberculomas generally resolve with antituberculous therapy; in some cases, they may heal with calcification.
        </p>
        <p>
         A bedside score (MASH-P) including five variables (modified Barthel index score  (
         <a class="graphic graphic_table graphicRef77371" href="/z/d/graphic/77371.html" rel="external">
          table 6
         </a>
         ) [M], age [A], stage of tuberculous meningitis [S], presence of hydrocephalus [H], and papilledema [P]), may be useful to predict probability of death in immunocompetent patients with tuberculous meningitis [
         <a href="#rid52">
          52
         </a>
         ]. The score ranges from 0 to 10, with a higher score correlating with higher probability of death; those with a score of 0 had 1.7 percent risk of death, while those with score of 10 had 65 percent risk of death.
        </p>
        <p>
         Factors that may be associated with better prognosis among adults with tuberculous meningitis include higher Glasgow Coma Scale and a higher plasma sodium concentration [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Drug resistance has been associated with diminished prognosis among patients with central nervous system (CNS) tuberculosis (TB). One study in Vietnam including 180 adults with tuberculous meningitis combined
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         and
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         resistance (observed in 5 percent of cases) was strongly predictive of death (relative risk of death 11.6, 95% CI 5.2-26.3) [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Concomitant Strongyloides stercoralis
         <em>
          infestation may modulate the inflammatory response to
         </em>
         M. tuberculosis
         <em>
          infection. In one study including
         </em>
         668 patients with tuberculous meningitis, 9.4 percent of patients tested positive for S. stercoralis
         <em>
          (via serology, stool microscopy, or and/or stool polymerase chain reaction)
         </em>
         [
         <a href="#rid55">
          55
         </a>
         ]. Concomitant S. stercoralis infection was associated with lower cerebral spinal fluid (CSF) neutrophil counts and lower CSF proinflammatory cytokines.
        </p>
        <p class="headingAnchor" id="H1462533826">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111822.html" rel="external">
          "Society guideline links: Diagnosis and treatment of tuberculosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1391769160">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – Prompt antituberculous therapy is essential in the treatment of central nervous system (CNS) tuberculosis (TB). Because of the high associated mortality, treatment should be initiated when the diagnosis is suspected and not deferred until a diagnosis is established. (See
         <a class="local">
          'Treatment'
         </a>
         above and
         <a class="local">
          'Outcomes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antituberculous therapy
         </strong>
         – In general, treatment of CNS TB consists of an intensive phase (four drugs administered for two months) followed by a continuation phase (2 drugs administered for an additional 7 to 10 months), for a total treatment duration of 9 to 12 months  (
         <a class="graphic graphic_table graphicRef127916" href="/z/d/graphic/127916.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Antituberculous therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intensive phase
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Adults
         </strong>
         – For adults, the intensive phase consists of four drugs (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and a fourth agent) administered for two months. Options for the fourth agent include
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         . This approach is derived from management of pulmonary TB, the evidence for which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Antituberculous therapy'
         </a>
         and
         <a class="local">
          'Traditional regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Children
         </strong>
         – For children, the intensive phase consists of four drugs (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and either
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         or an aminoglycoside [in place of
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , given difficulty associated with monitoring for ethambutol-associated optic neuritis]) administered for two months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Continuation phase
         </strong>
         – For adults and children, the continuation phase consists of two drugs (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         and
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ); we suggest a duration of 7 to 10 months over a shorter duration (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Traditional regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-resistant infection
         </strong>
         – For patients with isoniazid-resistant CNS TB, we favor treatment with daily
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and a fluoroquinolone. This approach is derived from management of drug-resistant pulmonary TB, the evidence for which is discussed separately. In addition, the duration of therapy should be extended to 18 to 24 months, taking into account the severity of illness, clinical response to therapy, and the patient's immune status. (See
         <a class="local">
          'Drug resistant infection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids
         </strong>
         – The approach to use of glucocorticoids depends on the clinical presentation:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Meningitis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Patients without HIV infection
         </strong>
         – For patients with tuberculous meningitis (established or suspected) in the absence of HIV infection, we recommend adjunctive glucocorticoid therapy (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). Clinical trial data have found that such treatment improves short-term survival.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Patients with HIV infection
         </strong>
         – For patients with HIV and tuberculous meningitis (established or suspected), we suggest adjunctive glucocorticoid therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). While thus far clinical data have not demonstrated improved survival, it is possible that glucocorticoid therapy may confer a small reduction in mortality, with no increased risk of significant adverse effects. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tuberculoma
         </strong>
         – For patients with tuberculoma, we suggest adjunctive glucocorticoid therapy for patients with cerebral edema (particularly when edema is out of proportion to mass effect in the setting of associated altered mental status or focal neurologic deficits), and/or elevated intracranial pressure (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Tuberculoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Spinal arachnoiditis
         </strong>
         – For patients with spinal arachnoiditis, we suggest adjunctive glucocorticoid therapy for patients with spinal block (cerebrospinal fluid protein ≥500 mg/dL) and/or patients with acute cord compression (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Spinal arachnoiditis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transverse myelitis
         </strong>
         – For patients with tuberculous transverse myelitis (established or suspected), we suggest adjunctive glucocorticoid therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Transverse myelitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiretroviral therapy
         </strong>
         – For patients with HIV infection and CNS TB who are not already on antiretroviral therapy (ART), we suggest deferral of ART until eight weeks after starting TB treatment, regardless of CD4 count (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Antiretroviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paradoxical worsening
         </strong>
         – Development of immune reconstitution inflammatory syndrome (IRIS) occurs in approximately one-third of patients with CNS TB; it typically manifests with paradoxical worsening within three months of antituberculous therapy and may cause severe or fatal neurologic complications. The management of TB-associated IRIS is discussed separately. (See
         <a class="local">
          'Paradoxical worsening'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8030.html" rel="external">
          "Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy", section on 'Immune reconstitution inflammatory syndrome'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment. World Health Organization. Available at: https://www.who.int/publications/i/item/9789240048126 (Accessed on June 26, 2022).
         </li>
         <li class="breakAll">
          World Health Organization. WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents. https://www.who.int/publications/i/item/9789240046764 (Accessed on April 04, 2022).
         </li>
         <li class="breakAll">
          World Health Organization. Rapid communication on updated guidance on the management of tuberculosis in children and adolescents. https://www.who.int/publications-detail-redirect/9789240033450 (Accessed on September 27, 2021).
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonard JM. Central Nervous System Tuberculosis. Microbiol Spectr 2017; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009; 59:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilheu JA, Maglio F, Cetrangolo R, Pleus AD. Concentrations of ethambutol in the cerebrospinal fluid after oral administration. Tubercle 1971; 52:117.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Treatment of tuberculosis: guidelines. 2nd ed, 2010. https://www.tbonline.info/media/uploads/documents/treatment_of_tuberculosis-_guidelines_for_national_programmes_%282010%29.pdf (Accessed on January 22, 2024).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) 2010; 90:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heemskerk AD, Bang ND, Mai NT, et al. Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis. N Engl J Med 2016; 374:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svensson EM, Dian S, Te Brake L, et al. Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials. Clin Infect Dis 2020; 71:1817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cresswell FV, Meya DB, Kagimu E, et al. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clin Infect Dis 2021; 73:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Loenhout-Rooyackers JH, Keyser A, Laheij RJ, et al. Tuberculous meningitis: is a 6-month treatment regimen sufficient? Int J Tuberc Lung Dis 2001; 5:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sulis G, Tavaziva G, Gore G, et al. Comparative Effectiveness of Regimens for Drug-Susceptible Tuberculous Meningitis in Children and Adolescents: A Systematic Review and Aggregate-Level Data Meta-Analysis. Open Forum Infect Dis 2022; 9:ofac108.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Global tuberculosis control: Surveillance, planning, financing: WHO report 2008. https://apps.who.int/iris/handle/10665/43831 (Accessed on October 13, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heemskerk AD, Nguyen MTH, Dang HTM, et al. Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen. Clin Infect Dis 2017; 65:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg RK, Jain A, Malhotra HS, et al. Drug-resistant tuberculous meningitis. Expert Rev Anti Infect Ther 2013; 11:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg RK, Rizvi I, Malhotra HS, et al. Management of complex tuberculosis cases: a focus on drug-resistant tuberculous meningitis. Expert Rev Anti Infect Ther 2018; 16:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akkerman OW, Odish OF, Bolhuis MS, et al. Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis. Clin Infect Dis 2016; 62:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upton CM, Steele CI, Maartens G, et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J Antimicrob Chemother 2022; 77:1720.
          </a>
         </li>
         <li class="breakAll">
          Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. NIH's Office of AIDS Research, 2023. Available at: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/mycobacterium-0?view=full (Accessed on December 11, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351:1741.
          </a>
         </li>
         <li class="breakAll">
          Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. (Accessed on July 18, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra UK, Kalita J, Sagar B, Bhoi SK. Does adjunctive corticosteroid and aspirin therapy improve the outcome of tuberculous meningitis? Neurol India 2018; 66:1672.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997; 99:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girgis NI, Farid Z, Kilpatrick ME, et al. Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatr Infect Dis J 1991; 10:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2016; 4:CD002244.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1 (Accessed on June 08, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donovan J, Bang ND, Imran D, et al. Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults. N Engl J Med 2023; 389:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasserman S, Harrison TS. Tuberculous Meningitis - New Approaches Needed. N Engl J Med 2023; 389:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manesh A, Gautam P, Kumar D SS, et al. Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study. Clin Infect Dis 2023; 77:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rock RB, Olin M, Baker CA, et al. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 2008; 21:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harder E, Al-Kawi MZ, Carney P. Intracranial tuberculoma: conservative management. Am J Med 1983; 74:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traub M, Colchester AC, Kingsley DP, Swash M. Tuberculosis of the central nervous system. Q J Med 1984; 53:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalasani R, Goonathilake MR, Waqar S, et al. The Outcome of Surgical Intervention (Ventriculoperitoneal Shunt and Endoscopic Third Ventriculostomy) in Patients With Hydrocephalus Secondary to Tuberculous Meningitis: A Systematic Review. Cureus 2022; 14:e25317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg RK, Paliwal V, Malhotra HS. Tuberculous optochiasmatic arachnoiditis: a devastating form of tuberculous meningitis. Expert Rev Anti Infect Ther 2011; 9:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh AK, Malhotra HS, Garg RK, et al. Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis. BMC Infect Dis 2016; 16:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009; 48:e96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asselman V, Thienemann F, Pepper DJ, et al. Central nervous system disorders after starting antiretroviral therapy in South Africa. AIDS 2010; 24:2871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuon FF, Mulatti GC, Pinto WP, et al. Immune reconstitution inflammatory syndrome associated with disseminated mycobacterial infection in patients with AIDS. AIDS Patient Care STDS 2007; 21:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CH, Lui CC, Liu JW. Immune reconstitution syndrome in a patient with AIDS with paradoxically deteriorating brain tuberculoma. AIDS Patient Care STDS 2007; 21:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SMITH HV. TUBERCULOUS MENINGITIS. Int J Neurol 1964; 4:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 2013; 56:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marais S, Van Toorn R, Chow FC, et al. Management of intracranial tuberculous mass lesions: how long should we treat for? Wellcome Open Res 2019; 4:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg RK, Malhotra HS, Gupta R. Spinal cord involvement in tuberculous meningitis. Spinal Cord 2015; 53:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro-Flores A, Fernandez-Chinguel JE, Pacheco-Barrios N, et al. Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis. J Neurol 2022; 269:3482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verdon R, Chevret S, Laissy JP, Wolff M. Tuberculous meningitis in adults: review of 48 cases. Clin Infect Dis 1996; 22:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy DH, Fallon RJ. Tuberculous meningitis. JAMA 1979; 241:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizvi I, Malhotra HS, Garg RK, Kumar N. Derivation of a bedside score (MASH-P) to predict 6-month mortality in tuberculous meningitis. J Neurol Sci 2020; 415:116877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thao LTP, Wolbers M, Heemskerk AD, et al. Dynamic Prediction of Death in Patients With Tuberculous Meningitis Using Time-updated Glasgow Coma Scale and Plasma Sodium Measurements. Clin Infect Dis 2020; 70:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thwaites GE, Lan NT, Dung NH, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005; 192:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donovan J, Tram TTB, Phu NH, et al. Influence of Strongyloides stercoralis Coinfection on the Presentation, Pathogenesis, and Outcome of Tuberculous Meningitis. J Infect Dis 2022; 225:1653.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 128001 Version 14.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.who.int/publications/i/item/9789240048126" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment. World Health Organization. Available at: https://www.who.int/publications/i/item/9789240048126 (Accessed on June 26, 2022).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.who.int/publications/i/item/9789240046764" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : World Health Organization. WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents. https://www.who.int/publications/i/item/9789240046764 (Accessed on April 04, 2022).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.who.int/publications-detail-redirect/9789240033450" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : World Health Organization. Rapid communication on updated guidance on the management of tuberculosis in children and adolescents. https://www.who.int/publications-detail-redirect/9789240033450 (Accessed on September 27, 2021).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28281443" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Central Nervous System Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19643501" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5560732" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Concentrations of ethambutol in the cerebrospinal fluid after oral administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5560732" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Concentrations of ethambutol in the cerebrospinal fluid after oral administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20709598" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26760084" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31665299" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33693537" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11716339" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Tuberculous meningitis: is a 6-month treatment regimen sufficient?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35673608" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Comparative Effectiveness of Regimens for Drug-Susceptible Tuberculous Meningitis in Children and Adolescents: A Systematic Review and Aggregate-Level Data Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35673608" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparative Effectiveness of Regimens for Drug-Susceptible Tuberculous Meningitis in Children and Adolescents: A Systematic Review and Aggregate-Level Data Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28472255" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23750732" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Drug-resistant tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30359140" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Management of complex tuberculosis cases: a focus on drug-resistant tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26534926" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35257182" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35257182" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21596680" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15496623" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15496623" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30504561" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Does adjunctive corticosteroid and aspirin therapy improve the outcome of tuberculous meningitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30504561" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Does adjunctive corticosteroid and aspirin therapy improve the outcome of tuberculous meningitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9024451" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2041662" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Dexamethasone adjunctive treatment for tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27121755" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Corticosteroids for managing tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27121755" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Corticosteroids for managing tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37819954" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37819958" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Tuberculous Meningitis - New Approaches Needed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37405816" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18400795" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Central nervous system tuberculosis: pathogenesis and clinical aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6837585" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Intracranial tuberculoma: conservative management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6709824" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Tuberculosis of the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35637922" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The Outcome of Surgical Intervention (Ventriculoperitoneal Shunt and Endoscopic Third Ventriculostomy) in Patients With Hydrocephalus Secondary to Tuberculous Meningitis: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21905782" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Tuberculous optochiasmatic arachnoiditis: a devastating form of tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27329253" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19405867" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21045634" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Central nervous system disorders after starting antiretroviral therapy in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17711377" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Immune reconstitution inflammatory syndrome associated with disseminated mycobacterial infection in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17461717" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Immune reconstitution syndrome in a patient with AIDS with paradoxically deteriorating brain tuberculoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14296900" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : TUBERCULOUS MENINGITIS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23097584" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32047859" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Management of intracranial tuberculous mass lesions: how long should we treat for?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25896347" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Spinal cord involvement in tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35288778" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8783697" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Tuberculous meningitis in adults: review of 48 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/102806" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32408191" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Derivation of a bedside score (MASH-P) to predict 6-month mortality in tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30944929" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Dynamic Prediction of Death in Patients With Tuberculous Meningitis Using Time-updated Glasgow Coma Scale and Plasma Sodium Measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15942897" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33104201" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Influence of Strongyloides stercoralis Coinfection on the Presentation, Pathogenesis, and Outcome of Tuberculous Meningitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
